Cellular accumulation of the anticancer agent cisplatin: A review

British Journal of Cancer

Volumn 67, Issue 6, 1993, Pages 1171-1176

  Gately, D P ^a   Howell, S B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ION CHANNEL;

CELLULAR DISTRIBUTION; DIFFUSION; DRUG ACCUMULATION; DRUG EXCRETION; DRUG RESISTANCE; DRUG TRANSPORT; DRUG UPTAKE; HEAD AND NECK CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TESTIS CARCINOMA;

ANIMAL; CISPLATIN; HUMAN; NEOPLASMS, EXPERIMENTAL; SUPPORT, NON-U.S. GOV'T;

EID: 0027233829     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1993.221     Document Type: Article

References (42)

1. ANDREWS, P.A. (1991). Lack of inhibition of DDP uptake by platinum analogs. (Personal communication).
2. ANDREWS, P.A. & ALBRIGHT, K.A. (1991). Role of membrane ion transport in cisplatin accumulation. In Platinum and other metal coordination compounds in cancer chemotherapy, Howell, S.B. (ed). pp. 151-159. Plenum Press: New York, NY.
3. ANDREWS, P.A. & HOWELL, S.B. (1990). Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35-43.
4. ANDREWS, P.A., JONES, J.A., VARKI, N.M. & HOWELL, S.B. (1990). Rapid emergence of acquired ds-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Comm., 2, 93-100.
5. +-adenosine triphosphatase in the accumulation of as-diamminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res., 51, 3677-3681.
6. ANDREWS, P.A., MANN, S.C., VELURY, S. & HOWELL, S.B. (1987). Cisplatin uptake mediated cisplatin-resistance in human ovarian carcinoma cells. In Platinum and other metal coordination compounds in cancer chemotherapy, Nicolini, M. (ed.). pp. 248-254. Martinus Nijhoff Publishing: Padua, Italy.
7. ANDREWS, P.A., VELURY, S., MANN, S.C. & HOWELL, S.B. (1988). cw-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res., 48, 68-73.
8. BASU, A., TEICHER, B.A. & LAZO, J.S. (1990). Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J. Biol. Chem., 265, 8451-8457.
9. BERNAL, S.D., WONG, Y. C., KAKEFUDA, M. & URBANO, A.G. (1991). A new membrane protein associated with resistance to cis-platinum and methotrexate. In Proceeding of the sixth international symposium on platinum and other metal coordination compounds in cancer chemotherapy, Howell, S.B. (ed.). pp. 323-334. Plenum Press: San Diego, CA.
10. BINKS, S.P. & DOBROTA, M. (1990). Kinetics and mechanics of uptake of platinum-based pharmaceuticals by the rat small intestine. Biochem. Pharmacol, 40, 1329-1336.
11. BYFIELD, J.E. & CALABRO-JONES, P.M. (1981). Carrier-dependent and carrier-independent transport of anti-cancer alkylating drugs. Nature, 294, 281-283.
12. DORNISH, J.M., MELVIK, J.E. & PETTERSEN, E.O. (1986). Reduced cellular uptake of as-dichlorodiammineplatinum(II) by ben- zaldehyde. Anticancer Res., 6, 583-588.
13. DORNISH, J.M. & PETTERSEN, E.O. (1985). Protection from cis- dichlorodiammineplatinum-induced cell inactivation by aldehydes involves cell membrane amino groups. Cancer Letters, 29, 235-243.
14. DORNISH, J.M., PETTERSEN, E.O. & OFTEBRO, R. (1987). Synergistic cell inactivation by cis-dichlorodiammineplatinum(II) in combination with l-propargyl-5-chloropyrimidin-2-one. Br. J. Cancer, 56, 273-278.
15. DORNISH, J.M., PETTERSEN, E.O. & OFTEBRO, R. (1989). Modifying effect of cinnamaldehyde and cinnamaldehyde derivatives on cell inactivation and cellular uptake of cw-diamminedichloroplatinum (II) in human NHIK 3025 cells. Cancer Res., 49, 3917-3921.
16. DORNISH, J.M., PETTERSEN, E.O., OFTEBRO, R. & MELVIK, J.E. (1984). Reduction of cw-dichlorodiammineplatinum(II)-induced cell inactivation by benzaldehyde. Eur. J. Clin. Oncol., 20, 1287-1293.
17. GALE, G.R., MORRIS, C.R., ATKINS, L.M. & SMITH, A.B. (1973). Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents. Cancer Res., 33, 813-818.
18. HOWELL, S B., VICK, J., ANDREWS, P.A., VELURY, S. & SANGA, R. (1987). Biochemical modulation of cisplatin. In Platinum and other metal coordination compounds in cancer chemotherapy, Nicolini, M. (ed.). pp. 228-234. Martinus Nijhoff Publishing: Padua, Italy.
19. HROMAS, R.A., NORTH, J.A. & BURNS, C.P. (1987). Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Letters, 36, 197-201.
20. ISONISHI, S., ANDREWS, P.A. & HOWELL, S.B. (1990). Increased sensitivity to c/s-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-0- tetradecanoylphorbol 13-acetate. J. Biol. Chem., 265, 3623-3627.
21. ISONISHI, S., HOM, D.K., THIEBAUT, F.B., MANN, S.C., ANDREWS, P.A., BASU, A., LAZO, J.S., EASTMAN, A. & HOWELL, S.B. (1991). Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resitance to cisplatin. Cancer Res., 51, 5903-5909.
22. JEKUNEN, A.J., SHALINSKY, D R., HEATH, D.D., KHATIBI, S., ALBRIGHT, K.D. & HOWELL, S.B. (1992a). Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane using digitonin in vitro and in vivo. In Proceedings of the Eighty-Third Annual Meeting of the American Association for Cancer Research, (ed.). pp. 419.: San Diego, CA.
23. JEKUNEN, A.J., VICK, J., SANGA, R., CHAN, T.C.K. & HOWELL, S.B. (1992). Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. Cancer Res., (in press).
24. KAWAI, K., KAMATANI, N., GEORGES, E. & LING, V. (1990). Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to m-diamminedichloro- platinum(II). J. Biol. Chem., 265, 13137-13142.
25. KELLAND, L.R., MISTRY, P., ABEL, G., LOH, S.Y., O’NEILL, C.F., MURRER, B.A. & HARRAP, K.R. (1992). Mechanism-related circumvention of acquired c/s-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res., 52, 3857-3864.
26. KELLEY, S.L. & ROZENCWEIG, M. (1989). Resistance to platinum compounds: mechanisms and beyond. Eur. J. Clin. Oncol., 25, 1135-1140.
27. KIKUCHI, Y., IWANO, I., MIYAUCHI, M., SASA, H., NAGATA, I. & KUKI, E. (1990). Restorative effects of calmodulin antagonists on reduced cisplatin uptake by cisplatin-resistant human ovarian carcinoma cells. Gynecol Oncol., 39, 199-203.
28. KRAKER, A.J. & MOORE, C.W. (1988). Accumulaton of cw-diam- minedichloroplatinum(II) and platinum analogues by platinum- resistant murine leukemia cells in vitro. Cancer Res., 48, 9-13.
29. MANN, S.C., ANDREWS, P.A. & HOWELL, S.B. (1988). Comparison of lipid content, surface membrane fluidity, and temperature dependence of c/s-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Anticancer Res., 8, 1211-1216.
30. MANN, S.C., ANDREWS, P.A. & HOWELL, S.B. (1990). Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol, 25, 236-240.
31. MANN, S.C., ANDREWS, P.A. & HOWELL, S.B. (1991). Modulation of cw-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int. J. Cancer, 48, 866-872.
32. MELVIK, J.E., DORNISH, J.M. & PETTERSEN, E.O. (1992). The binding of ds-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro. Br. J. Cancer, 66, 260-265.
33. MELVIK, J.E. & PETTERSEN, E.O. (1988). Oxygen and temperature- dependent cytotoxicity and radiosensitizing effects of cis- dichlorodiammineplatinum(II) on human NHIK 3025 cells in vitro. Radiation Res., 114, 489-499.
34. MELVIK, J.E., PETTERSEN, E.O., GORDON, P.B. & SEGLEN, P.O. (1986). Increase in ds-dichlorodiammineplatinum(II) cytotoxicity upon reversible electropermeabilization of the plasma membrane in cultured human NHIK 3025 cells. Eur. J. Clin. Oncol., 22, 1523-1530.
35. MORIKAGE, T., BUNGO, M., INOMATA, M., YOSHIDA, M., OHMORI, T., FUJI WAR A, Y., NISHIO, K. & SAIJO, N. (1991). Reversal of cisplatin resistance with Amphotericin B in non-small cell lung cancer cell line. Jpn. J. Cancer Res., 82, 747-751.
36. NICOLSON, M.C., ORR, R.M., O’NEILL, C.F. & HARRAP, K.R. (1992). The role of platinum uptake and glutathione levels in LI210 cells sensitive and resistant to cisplatin, tetraplatin, or carboplatin. Neoplasma, 39, 189-195.
37. OGAWA, M., GALE, G.R. & KEIRN, S.S. (1975). Effects of cis- diamminedichloroplatinum (NSC 119875) on murine and human hemopoietic precursor cells. Cancer Res., 35, 1398-1401.
38. PEREZ, R.P., HAMILTON, T.C. & OZOLS, R.F. (1990). Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol. Ther., 48, 19-27.
39. SHIONOYA, S. & SCANLON, K.J. (1986). Properties of amino acid transport systems in K562 cells sensitive and resistant to cis- diamminedichloroplatinum(II). Cancer Res., 46, 3445-3448.
40. TIMMER-BOSSCHA, H., HOSPERS, G A P., MEIJER, C., MULDER, N.H., MUSKIET, F.A.J., MARTINI, I.A., UGES, D.R.A. & DE VRIES, E.G.E. (1989). Influence of docosahexaenoic acid on cisplatin resistance in a small cell lung carcinoma cell line. J. Natl Cancer Inst., 81, 1069-1075.
41. TIMMER-BOSSCHA, H., MULDER, N.H. & DE VRIES, E.G.E. (1992). Modulation of n’s-diamminedichloroplatinum(II) resistance: a review. Br. J. Cancer, 66, 227-238.
42. WAUD, W.R. (1987). Differential uptake of cw-diam-minedichloroplatinum(II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res., 47, 6549-6555.